TEGA Therapeutics
La Jolla
About TEGA Therapeutics
TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Last round: Grant (Dec 2020)
- Website: tegatherapeutics.com
- Phone: 619-838-8579
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/tega-therapeutics-26915 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.